|Bid||11.81 x 1100|
|Ask||11.88 x 800|
|Day's Range||11.56 - 13.00|
|52 Week Range||9.65 - 18.16|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe’s Board as the Company Sets to Accelerate Personalized Healthcare Based on Human GeneticsSUNNYVALE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that, following the June 16 closing of the previously announced business combination between 23andMe, Inc. and VG Acquisition Corp. (“VGAC”), Dr. Valerie Montgomery Rice, the president and
DNA testing company 23andMe started trading on Thursday under the ticker ‘ME’. Anne Wojcicki, 23andMe CEO, joins Yahoo Finance Live to discuss the company going public and the future of genetic testing post-COVID.
Myles Udland, Brian Sozzi, and Julie Hyman breakdown 23andMe going public with the help of Richard Branson, and how the company plans to change its business model to make itself more profitable in the market.